The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis

Molecular Therapy

Volumn 1, Issue 2, 2000, Pages 130-144

  Meng, Raymond D ^a   McDonald III, E Robert ^a   Sheikh, M Saeed ^b   Fornace Jr , Albert J ^c   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; KILLER DR5; p53; TRAIL; TRID; TRUNDD (DcR2, TRAIL R4)

Indexed keywords

COMPLEMENTARY DNA; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN P53; TNFRSF10B PROTEIN, HUMAN; TNFRSF10C PROTEIN, HUMAN; TNFRSF10D PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADENOVIRUS; APOPTOSIS; ARTICLE; BIOLOGICAL MODEL; CELL CULTURE; CHEMISTRY; COLON TUMOR; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MUTATION; NORTHERN BLOTTING; OVARY TUMOR; PATHOLOGY; PLASMID; PROTEIN SYNTHESIS; PROTEIN TERTIARY STRUCTURE; TIME; WESTERN BLOTTING;

ADENOVIRIDAE; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; COLONIC NEOPLASMS; DNA, COMPLEMENTARY; FEMALE; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MUTATION; OVARIAN NEOPLASMS; PLASMIDS; PROTEIN BIOSYNTHESIS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034136792     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2000.0025     Document Type: Article

References (47)

1. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
2. El-Deiry W. S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8:1998;345-357.
3. Meng R. D., El-Deiry W. S. Tumor suppressor genes as targets for cancer gene therapy. Lattime E. C., Gerson S. L. Gene Therapy of Cancer. 1998;3-20 Academic Press, San Diego.
4. Burns T. F., El-Deiry W. S. The p53 pathway and apoptosis. J. Cell. Physiol. 181:1999;231-239.
5. Hengartner M. O. Death cycle and Swiss army knives. Nature. 391:1998;441-442.
6. Polyak K., Xia Y., Zweier J. L., Kinzler K. W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
7. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
8. Wu G. S., Burns T. F., McDonald E. R. III, Jiang W., Meng R., Krantz I. D., Kao G., Gan D. D., Zhou J. Y., Muschel R., Hamilton S. R., Spinner N. B., Markowitz S., Wu G., El-Deiry W. S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143.
9. Chaudhary P. M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa B pathway. Immunity. 7:1997;821-830.
10. MacFarlane M., Ahmad M., Srinivasula S. M., Fernandes-Alnemri T., Cohen G. M., Alnemri E. S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272:1997;25417-25420.
11. Pan G., Ni J., Wei Y. F., Yu G. L., Gentz R., Dixit V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:1997;815-818.
12. Schneider P., Bodmer J. L., Thome M., Hofmann K., Holler N., Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett. 416:1997;329-334.
13. Schneider P., Thome M., Burns K., Bodmer J. L., Hofmann K., Kataoka T., Holler N., Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappa B. Immunity. 7:1997;831-836.
14. Screaton G. R., Mongkolsapaya J., Xu X. N., Cowper A. E., McMichael A. J., Bell J. I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:1997;693-696.
15. Sheridan J. P., Marsters S. A., Pitti R. M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C. L., Baker K., Wood W. I., Goddard A. D., Godowski P., Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
16. Walczak H., Degli-Esposito M. A., Johnson R. S., Smolak P. J., Waugh J. Y., Boiani N., Timour M. S., Gerhart M. J., Schooley K. A., Smith C. A., Goodwin R. G., Rauch C. T. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:1997;5386-5397.
17. Knudson C. M., Tung K. S. K., Tourtellotte W. G., Brown G. A. J., Korsmeyer S. J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 270:1995;96-99.
18. Fuchs E. J., McKenna K. A., Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1 independent activation of CPP32. Cancer Res. 57:1997;2550-2554.
19. Sheikh M. S., Burns T. F., Huang Y., Wu G. S., Amundson S., Brooks K. S., Fornace A. J. Jr., El-Deiry W. S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α Cancer Res. 58:1998;1593-1598.
20. Pai S. I., Wu G. S., Ozoren N., Wu L., Jen J., Sidransky D., El-Deiry W. S. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 58:1998;3513-3518.
21. Wu G. S., Burns T. F., Zhan Y., Alnemri E. S., El-Deiry W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59:1999;2770-2775.
22. Degli-Esposito M. A., Dougall W. C., Smolak P. J., Waugh J. Y., Smith C. A., Goodwill R. G. The novel receptor TRAIL-R4 induces NF-kappa B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:1997;813-820.
23. Marsters S. A., Sheridan J. P., Pitti R. M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A. D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7:1997;1003-1006.
24. Mongkolsapaya J., Cowper A. E., Xu X. N., Morris G., McMichael A. J., Bell J. I., Screaton G. R. Cutting edge: Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand). A new receptor protecting lymphocytes from the death ligand TRAIL. J. Immunol. 160:1998;3-6.
25. Ashkenazi A., Dixit V. M. Death receptors: Signaling and modulation. Science. 281:1998;1305-1308.
26. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M. E. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:1998;439-459.
27. Pitti R. M., Marsters S. A., Lawrence D. A., Roy M., Kischkel F. C., Dowd P., Huang A., Donahue C. J., Sherwood S. W., Baldwin D. T., Godowski P. J., Wood W. I., Gurney A. L., Hillan K. J., Cohen R. L., Goddard A. D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:1998;699-703.
28. Sheikh M. S., Huang Y., Fernandez-Salas E. A., El-Deiry W. S., Friess H., Amundson S., Yin J., Meltzer S. J., Holbrook N. J., Fornace A. J. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 18:1999;4153-4159.
29. Wu G. S., El-Deiry W. S. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl2. Clin. Cancer Res. 2:1996;623-633.
30. Meng R. D., Shih H., Prabhu N. S., George D. L., El-Deiry W. S. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin. Cancer Res. 4:1998;251-259.
31. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
32. Prabhu N. S., Blagosklonny M. V., Zeng Y.-X., Wu G. S., Waldman T., El-Deiry W. S. Suppression of cancer cell growth by adenovirus expressing p21WAF1/CIP1 deficient in PCNA interaction. Clin. Cancer Res. 2:1996;1221-1229.
33. Meng R. D., Phillips P., El-Deiry W. S. p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. Int. J. Oncol. 14:1999;5-14.
34. Zhang H., Somasundaram K., Peng Y., Tian H., Zhang H., Bi D., Weber B. L., El-Deiry W. S. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene. 16:1998;1713-1721.
35. Prabhu N. S., Somasundaram K., Satyamoorthy K., Herlyn M., El-Deiry W. S. p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int. J. Oncol. 13:1998;5-9.
36. El-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y. S., Wiman K. G., Mercer W. E., Kastan M. B., Kohn K. W., Elledge S. J., Kinzler K. W., Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
37. Pan G., Ni J., Yu G. L., Wei Y. F., Dixit V. M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424:1998;41-45.
38. Yeh W. C., de la Pompa J. L., McCurrach M. E., Shu H.-B., Elia A. J., Shahinian A., Ng M., Wakeham A., Mitchell K., El-Deiry W. S., Lowe S. W., Goeddel D. V., Mak T. W. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 279:1998;1954-1958.
39. Zhang J., Cado D., Chen A., Kabra N. H., Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 392:1998;296-300.
40. 2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J. Biol. Chem. 273:1998;33091-33098.
41. Herr I., Wilhelm D., Bohler T., Angel P., Debatin K. M. JNK/SAPK activity is not sufficient for anticancer therapy-induced apoptosis involving CD95-L, TRAIL and TNF-alpha. Int. J. Cancer. 80:1999;417-424.
42. Tartaglia L. A., Ayres T. M., Wong G. H. W., Goeddel D. V. A novel domain within the 55 kD TNF receptor signals cell death. Cell. 74:1993;845-853.
43. Itoh N., Nagata S. A novel protein domain required for apoptosis: Mutational analysis of human Fas antigen. Cancer Res. 268:1993;10932-10937.
44. Phillips A. C., Ernst M. K., Bates S., Rice N. R., Vousden K. H. E2F-1 potentiates cell death by blocking anti-apoptotic signaling pathways. Molec. Cell. 4:1999;771-781.
45. Jiang Y., Woronicz J. D., Liu W., Goeddel D. V. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Nature. 283:1999;543-546.
46. Walczak H., Miller R. E., Ariail K., Gliniak B., Griffith T. S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R. G., Rauch C. T. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nature Med. 5:1999;157-163.
47. Blagosklonny M. V., El-Deiry W. S. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer. 67:1996;386-392.